Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Adult stem cells: from new cell sources to changes in methodology.

Pelacho B., Mazo M., Gavira JJ., Prósper F.

Clinical Trial on Cardiovascular Disease, published in J Cardiovasc Transl Res (2010) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
J Cardiovasc Transl Res (2010)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
21125433
DOI
10.1007/s12265-010-9245-z

Abstract (original English)

Cardiovascular diseases constitute the first cause of mortality and morbidity worldwide. Alternative treatments like transplantation of (stem) cell populations derived from several adult tissue sources, like the bone marrow, skeletal muscle, or even adipose tissue, have been already employed in diverse clinical trials. Results from these studies and previous animal studies have reached to the conclusion that stem cells induce a benefit in the treated hearts, which is exerted mainly through paracrine mechanisms and not through direct differentiation as it was initially expected. However, a strong technical limitation for the stem cell therapy, which is the low level of cell survival and engraftment, diminishes their potential. Thus, new strategies like combination of the cells with bioengineering techniques have been developed and are being subject of intense research, suggesting that new strategies may improve the efficacy of these therapies. In this review, we will discuss the different therapeutic approaches, drawbacks, and future expectations of new regenerative therapies for cardiovascular diseases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Adult Stem CellsAnimalsBioengineeringCell DifferentiationHeart DiseasesHumansMyocardiumMyocytes, CardiacParacrine CommunicationRegeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research